WOMEN CEO REPORT

Dr. Athena M. Countouriotis M.D. - Turning Point Therapeutics

Dr. Athena M. Countouriotis M.D.

Turning Point Therapeutics

Dr. Athena Countouriotis became president and chief executive officer and was named to the Turning Point Therapeutics board of directors in September 2018. She has broad oncology biotech leadership experience, guiding multiple development programs to approval. Her experience includes large and small molecule therapeutics in hematologic and solid tumor indications, with multiple regulatory approvals in the U.S. and Europe. She joined Turning Point Therapeutics in May 2018 as executive vice president and chief medical officer to advance the clinical development of repotrectinib. She previously served as senior vice president and chief medical officer for Adverum Biotechnologies, and before that as senior vice president and chief medical officer of Halozyme Therapeutics.

Year appointed: 2018